Lurbinectedin is a chemotherapy drug used for the treatment of certain types of cancer, including small cell lung cancer and advanced ovarian cancer. The duration of the treatment course with lurbinectedin can vary depending on several factors, including the type and stage of cancer being treated, as well as the patient's overall health and response to the medication.

According to DrugPatentWatch [1], the patent for lurbinectedin is set to expire in 2038, indicating that the drug is still under patent protection and is likely being actively marketed and prescribed. The article also notes that the drug has been granted orphan drug status by the FDA, which is typically reserved for drugs used to treat rare diseases or conditions.

A review article published in the Journal of Clinical Medicine [2] notes that lurbinectedin is typically administered intravenously once every three weeks, with the specific dosage and treatment duration varying depending on the patient's individual circumstances. The article notes that the drug has shown promise in clinical trials for the treatment of small cell lung cancer and other types of solid tumors.

The FDA label for lurbinectedin [3] provides additional information on dosing and treatment duration. The recommended dose of the drug is 3.2 mg/m2 administered as an intravenous infusion over one hour every three weeks. The label notes that treatment with lurbinectedin should continue until disease progression or unacceptable toxicity occurs.

In summary, the duration of the treatment course with lurbinectedin can vary depending on the type and stage of cancer being treated, as well as the patient's overall health and response to the medication. However, the drug is typically administered intravenously once every three weeks, with treatment continuing until disease progression or unacceptable toxicity occurs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf